^
Association details:
| Biomarker: | EGFR L858R |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
137P-Epidermal Growth Factor Receptor mutation status and response to Tyrosine Kinase Inhibitors in advanced Chinese female lung squamous cell carcinoma: a retrospective study
Published date:
03/17/2021
Excerpt:
Positive EGFR mutations were found in 29.9% (46/154) of female lung SCC patients, including twenty-three 19del mutation (14.9%), twenty-one 21L858R mutation (13.6%) and other mutations (1.4%, 21861Q and 20ins). For 45 EGFR positive mutation female SCC patients, the median progression-free survival (PFS) of patients who received EGFR-TKI therapy (n = 38) was 8.0 months (95% CI, 5.4–10.7 months), which was significantly longer than patients who were treated with chemotherapy (8.0 vs 3.2 months, p = 0.024), and the median overall survival (OS) was also longer (24.9 months vs 13.9 months, p = 0.020).
